Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Aptinyx

Aptinyx
2015 FOUNDED
PUBLIC STATUS
61-70 EMPLOYEES
APTX STOCK SYMBOL
$3.33 SHARE PRICE (As of Friday Closing)
Description

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 909 Davis Street
  • Suite 600
  • Evanston, IL 60201
  • United States

+1 (847) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Aptinyx’s full profile, request a free trial.

Aptinyx Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$3.27 - $32.25 $112M $3.33 -$2.92 375K 33.6M

Aptinyx Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value (14,710) 594,296
Revenue 5,000 6,574 4,962 9,792
EBITDA (57,849) (52,824) (31,663) (15,293)
Net Income (58,320) (53,281) (32,068) (15,478)
Total Assets 140,993 155,614 97,322 18,646
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aptinyx Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Aptinyx‘s full profile, request access.

Request full access to PitchBook

Aptinyx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Aptinyx‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Aptinyx Competitors (12)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cortexyme Formerly VC-backed South San Francisco, CA 00 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Lexington, MA 00 00000 000000000 00000
0000000 Formerly VC-backed South San Francisco, CA 00 00000 00000000 00000
0 000000000000 Venture Capital-Backed Salt Lake City, UT 000.00 00000 00000 000.00
000000 00000000000 Venture Capital-Backed Cambridge, MA 0 000.00 00000000000 000.00
To view this company’s complete list of competitors, request access »

Aptinyx Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Aptinyx‘s full profile, request access.

Request full access to PitchBook

Aptinyx Executive Team (10)

Name Title Board
Seat
Contact
Info
Norbert Riedel Ph.D President, Chief Executive Officer & Board Member
Ashish Khanna Chief Financial Officer & Chief Business Officer
David Houck Ph.D Chief Development Officer
Joseph Moskal Ph.D Chief Scientific Officer
Andy Kidd Chief Commercial Officer
You’re viewing 5 of 10 executives. Get the full list »

Aptinyx Board Members (10)

Name Representing Role Since Contact
Info
Adam Koppel Ph.D Bain Capital Board Member 000 0000
James Topper Ph.D Frazier Healthcare Partners Board Member 000 0000
Liam Ratcliffe Ph.D New Leaf Venture Partners Board Member 000 0000
Norbert Riedel Ph.D Aptinyx President, Chief Executive Officer & Board Member 000 0000
Patrick Enright Longitude Capital Board Member 000 0000

5 Former Board Members

You’re viewing 5 of 10 board members. Get the full list »